LUNG CANCER

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

South Florida’s diverse lung cancer cases fuel genomic breakthroughs, push screening beyond smokers, and accelerate 2026 targeted-therapy progress.

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need for improved access to targeted therapies.

The FDA reviews ivonescimab for advanced lung cancer treatment, showing promising trial results and potential to enhance patient outcomes post-TKI therapy.

A new study reveals that savolitinib and osimertinib significantly enhance survival in advanced EGFR-mutated lung cancer, outperforming traditional chemotherapy.

New research highlights the potential of nogapendekin alfa inbakicept to enhance survival in patients with advanced lung cancer resistant to standard therapies.

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous non–small cell lung cancer.

A groundbreaking biologics license application for ivonescimab targets advanced lung cancer, promising improved outcomes for patients with EGFR mutations.

The FDA designates zoldonrasib as a breakthrough therapy for KRAS G12D-mutated lung cancer, highlighting its promising efficacy and safety profile.

A new trial explores the effectiveness of calderasib combined with pembrolizumab for advanced lung cancer patients with the KRAS G12C mutation.

Sevabertinib receives breakthrough therapy designation for treating advanced HER2-mutant non-small cell lung cancer, promising new hope for patients.

2025 marks a transformative year in thoracic oncology, showcasing groundbreaking FDA approvals for targeted therapies in lung cancer treatment.

A new study reveals that common chronic medications do not impact the effectiveness of immune checkpoint inhibitors in metastatic lung cancer treatment.

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

Silevertinib shows promising antitumor activity in NSCLC and plans for a phase 2 trial in glioblastoma, targeting unmet oncology needs.

The OptiTROP-Lung05 trial shows promising results for sacituzumab tirumotecan combined with pembrolizumab in treating advanced non–small cell lung cancer.

A new subcutaneous formulation of toripalimab shows comparable efficacy to the intravenous version, enhancing convenience for lung cancer patients.

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and increases treatment-related risks.

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.

Zipalertinib shows promise as a treatment for advanced NSCLC with EGFR mutations, demonstrating significant response rates in recent trials.

The FDA reviews zidesamtinib for advanced ROS1+ NSCLC, promising new treatment options for patients resistant to current therapies.

Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options.